The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Performance Characteristics of CA 19-9 Radioimmunoassay and Clinical Significance of Serum CA 19-9 Assay in Patients with Malignancy

CA 19-9 방사면역측정법의 기본적 검토 및 악성종양환자에서의 혈청 CA 19-9치의 임상적 의의에 관한 연구

  • Kim, Sang-Eun (Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Shong, Young-Kee (Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Cho, Bo-Youn (Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Kim, Noe-Kyeong (Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Koh, Chang-Soon (Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Lee, Mun-Ho (Department of Internal Medicine, College of Medicine, Seoul National University) ;
  • Hong, Seong-Woon (Department of Nuclear Medicine, Korea Cancer Center Hospital) ;
  • Hong, Kee-Suk (Seoul Medical Clinic)
  • 김상은 (서울대학교 의과대학 내과학교실) ;
  • 송영기 (서울대학교 의과대학 내과학교실) ;
  • 조보연 (서울대학교 의과대학 내과학교실) ;
  • 김노경 (서울대학교 의과대학 내과학교실) ;
  • 고창순 (서울대학교 의과대학 내과학교실) ;
  • 이문호 (서울대학교 의과대학 내과학교실) ;
  • 홍성운 (원자력병원 핵의학과) ;
  • 홍기석 (서울내과병원)
  • Published : 1985.05.20
Download PDF
⟨ Previous Next ⟩

Abstract

To evaluate the performance characteristics of CA 19-9 radioimmunoassay and the clinical significance of serum CA 19-9 assay in patients with malignancy, serum CA 19-9 levels were measured by radioimmunoassay using monoclonal antibody in 135 normal controls, 81 patients with various untreated malignancy, 9 patients of postoperative colon cancer without recurrence and 20 patients with benign gastrointestinal diseases, who visited Seoul National University Hospital from June, 1984 to March, 1985. The results were as follows; 1) The CA 19-9 radioimmunoassay was simple to perform and can be completed in one work day. And the between-assay reproducibility and the assay recovery were both excellent. 2) The mean serum CA 19-9 level in 135 normal controls was $8.4{\pm}4.2U/mL$. Normal upper limit of serum CA 19-9 was defined as 21.0 U/mL. 4 out of 135(3.0%) normal controls showed elevated CA 19-9 levels above the normal upper limit. 3) One out of 20(5.0%) patients with benign gastrointestinal diseases showed elevated serum CA 19-9 level above the normal upper limit. 4) In 81 patients with various' untreated malignancy, 41 patients(50.6%) showed elevated serum CA 19-9 levels. 66.7% of 18 patients with colorectal cancer, 100% of 2 patients with pancreatic cancer, 100% of 3 patients with common bile duct cancer, 47.1% of 17 patients with stomach cancer, 28.6% of 28 patients with hepatoma and 60.0% of 5 other gastrointestinal tract cancers showed elevated serum CA 19-9 levels. 5) The sensitivities of serum CA 19-9 related to resectability in colorectal and stomach cancer were 33.3% in resectable colorectal cancer, 83.3% in unresectable colorectal cancer, 41.7% in resectable stomach cancer, 60.0% in unresectable stomach cancer respectively. 6) The sensitivity of serum CA 19-9 in 9 patients of postoperative colorectal cancer without recurrence were 33.3% and significantly decreased compared with that of untreated colorectal cancer, 66.7% (p<0.05). 7) In patients with colorectal cancer, simultaneous measurement of serum CA 19-9 and serum CEA levels increased sensitivities. From above results, we concluded that serum CA 19-9 radioimmunoassay is simple to perform and reproducible, and is a useful indicator reflecting tumor extent and responses to the treatment in patients with malignancy.

Keywords